AXT Inc (AXTI)

NASDAQInformation TechnologySemiconductorsSnapshot 2026-10-23

$52.08+1.01%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge AXT Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	77.45M
EPS	—	0.363
Annual ending 2026-12-31
Revenue	—	221.2M
EPS	—	0.856
Annual ending 2027-12-31
Revenue	—	482.53M
EPS	—	2.217

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Successful execution of long-term supply agreement with Casela	The company secured a long-term supply agreement supporting future sales.	Improving	Material breach or cancellation of supply agreement	Qualitative: New Lumentum agreement signed 2026-07-26; no breach reported AXT signed a Capacity Reservation Agreement with Lumentum for InP substrates on July 26, 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Return to positive earnings and margin improvement	A primary condition in AXT Inc's published investment case. The stated target is EPS >= $0.3 in FY26 and EPS >= $0.78 in FY27.	Improving	EPS remains negative or below $0.1 in FY26	Diluted EPS: $0.17 per share FY2026-Q2; GAAP. Published target: EPS >= $0.3 in FY26 and EPS >= $0.78 in FY27. Target period is not explicitly aligned with this observation. Source published Aug 13, 20260.17 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8ce66032-0951-42ca-8d8a-baf2282009c7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Sequential revenue growth in Q1 and beyond	A primary condition in AXT Inc's published investment case. The stated target is >= $26.9M revenue in 2026-Q1 and continued sequential growth.	Intact	Revenue falls below $23M in any quarter after 2026-Q1	Revenue: $47.589M FY2026-Q2; GAAP. Published target: >= $26.9M revenue in 2026-Q1 and continued sequential growth. Target period is not explicitly aligned with this observation. Source published Aug 13, 202647,589,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8ce66032-0951-42ca-8d8a-baf2282009c7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of last 2 quarters. Revenue grew sequentially from $26.9M in 2026-Q1 to $47.6M in 2026-Q2, driven by indium phosphide demand for AI infrastructure. The financial results confirm management's stated goal of sequential revenue growth is delivering. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$0.78 → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.22B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.78	$222,351,000	5 / 5
2026-07-25	$0.78	$222,351,000	5 / 5
2026-07-26	$0.78	$222,351,000	5 / 5
2026-07-27	Unavailable	Unavailable	3 / 4
2026-07-28	$0.78	$222,351,000	5 / 5
2026-07-29	$0.78	$222,351,000	5 / 5
2026-07-30	$0.78	$222,351,000	5 / 5
2026-07-31	$0.78	$222,351,000	5 / 5
2026-08-01	$0.78	$222,351,000	5 / 5
2026-08-02	$2.23	$460,552,000	5 / 5
2026-08-03	$2.23	$460,552,000	5 / 5
2026-08-04	$2.23	$460,552,000	5 / 5
2026-08-05	$2.23	$460,552,000	5 / 5
2026-08-06	$2.23	$460,552,000	5 / 5
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	$2.23	$460,552,000	5 / 5
2026-08-09	$2.23	$460,552,000	5 / 5
2026-08-10	$2.23	$460,552,000	5 / 5
2026-08-11	$2.23	$460,552,000	5 / 5
2026-08-12	$2.23	$460,552,000	5 / 5
2026-08-13	$2.23	$460,552,000	5 / 5
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	3 / 4
2026-08-21	Unavailable	Unavailable	3 / 4
2026-08-22	Unavailable	Unavailable	3 / 4
2026-08-23	Unavailable	Unavailable	3 / 4
2026-08-24	Unavailable	Unavailable	3 / 4
2026-08-25	Unavailable	Unavailable	3 / 4
2026-08-26	Unavailable	Unavailable	3 / 4
2026-08-27	Unavailable	Unavailable	3 / 4
2026-08-28	Unavailable	Unavailable	3 / 4
2026-08-29	Unavailable	Unavailable	3 / 4
2026-08-30	Unavailable	Unavailable	3 / 4
2026-08-31	Unavailable	Unavailable	3 / 4
2026-09-01	Unavailable	Unavailable	3 / 4
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	Unavailable	3 / 4
2026-09-04	Unavailable	Unavailable	3 / 4
2026-09-05	Unavailable	Unavailable	3 / 4
2026-09-06	Unavailable	Unavailable	3 / 4
2026-09-07	Unavailable	Unavailable	3 / 4
2026-09-08	Unavailable	Unavailable	3 / 4
2026-09-09	Unavailable	Unavailable	3 / 4
2026-09-10	Unavailable	Unavailable	3 / 4
2026-09-11	Unavailable	Unavailable	3 / 4
2026-09-12	Unavailable	Unavailable	3 / 4
2026-09-13	Unavailable	Unavailable	3 / 4
2026-09-14	Unavailable	Unavailable	3 / 4
2026-09-15	Unavailable	Unavailable	3 / 4
2026-09-16	Unavailable	Unavailable	3 / 3
2026-09-17	Unavailable	Unavailable	3 / 3
2026-09-18	Unavailable	Unavailable	3 / 3
2026-09-19	Unavailable	Unavailable	3 / 3
2026-09-20	Unavailable	Unavailable	3 / 3
2026-09-21	Unavailable	Unavailable	3 / 3
2026-09-22	Unavailable	Unavailable	3 / 3
2026-09-23	Unavailable	Unavailable	3 / 3
2026-09-24	Unavailable	Unavailable	3 / 3
2026-09-25	Unavailable	Unavailable	3 / 3
2026-09-26	Unavailable	Unavailable	3 / 3
2026-09-27	Unavailable	Unavailable	3 / 3
2026-09-28	Unavailable	Unavailable	3 / 3
2026-09-29	Unavailable	Unavailable	3 / 3
2026-09-30	Unavailable	Unavailable	3 / 3
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	2
2026-06-01	3	2
2026-07-01	4	2
2026-08-01	4	2
2026-09-01	4	1
2026-10-01	4	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Return to positive earnings and margin improvementDiluted EPS: $0.17 per share
Sequential revenue growth in Q1 and beyondRevenue: $47.589M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

6.2%Typical daily move · historical

Downside history

-73.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

AXT Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business, not a proven durable compounder, because it remains loss-making and carries high risk. The long-term thesis is intact, but its signal has shifted from mildly favorable to mixed.

What's priced into AXT Inc

AXTI is expensive versus peers, with valuation supported in part by expectations for future growth opportunities. The expectations gap is positive, but confidence in that estimate is low, so the evidence does not show that expectations are clearly easy to meet.

What the fundamentals likely do

Near term, recent results show strong sequential revenue growth and improved gross margin, in line with management’s focus on expanding capacity for AI-related indium phosphide demand. The next-call guidance remains a key risk: a cut would matter, while recent earnings surprises have been trending down despite a low stated miss risk.

What AXT Inc hinges on

Over the next one to three years, the thesis hinges on whether capacity expansion can sustain revenue growth and improve the business while AXTI remains loss-making. Near term, weaker guidance could challenge the setup; continued strength among major technology companies or Fed rate cuts could support the sector backdrop, but neither resolves AXTI’s execution risk.